<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863575</url>
  </required_header>
  <id_info>
    <org_study_id>B3741002</org_study_id>
    <secondary_id>MIG</secondary_id>
    <secondary_id>MIG II</secondary_id>
    <nct_id>NCT02863575</nct_id>
  </id_info>
  <brief_title>A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled Study Comparing The Analgesic Efficacy And Safety Of A Single Oral Dose Of A Novel Fixed-dose Combination Of Ibuprofen 400 Mg With Caffeine 100 Mg To Ibuprofen 400 Mg And To Placebo In The Treatment Of Post-surgical Dental Pain In Otherwise Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An efficacy study assessing analgesic effect of ibuprofen/caffeine in post-surgical dental
      pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the analgesic efficacy of a fixed dose combination of
      ibuprofen/caffeine compared to ibuprofen alone and also to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Actual">April 6, 2018</completion_date>
  <primary_completion_date type="Actual">April 6, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPRID0-8</measure>
    <time_frame>0-8 hours</time_frame>
    <description>Time-weighted sum of pain relief rating (PRR) and pain intensity difference (PID) from 0 to 8 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPRID</measure>
    <time_frame>0-8 hours</time_frame>
    <description>Time-weighted sum of pain relief rating (PRR) and pain intensity difference (PID) scores over 2 hours (SPRID0-2), over 4 hours (SPRID0-4), over 6 hours (SPRID0-6) and over 8 hours (SPRID0-8, for IBU 400 mg with caffeine 100 mg versus placebo comparison) post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPID</measure>
    <time_frame>0-8 hours</time_frame>
    <description>Time-weighted sum of pain intensity difference (PID) scores over 2 hours (SPID0-2), over 4 hours (SPID0-4), over 6 hours (SPID0-6), and over 8 hours (SPID0-8) post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOTPAR</measure>
    <time_frame>0-8 hours</time_frame>
    <description>Time-weighted sum of pain relief rating (PRR) over 2 hours (TOTPAR0-2), over 4 hours (TOTPAR0-4), over 6 hours (TOTPAR0-6), and over 8 hours (TOTPAR0-8) post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRID</measure>
    <time_frame>0-8 hours</time_frame>
    <description>The sum of pain relief rating and pain intensity difference scores (PRID) at 0.25, 0.5, 1, 1.5, 2, 3, 4 5, 6, 7, and 8 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRR</measure>
    <time_frame>0-8 hours</time_frame>
    <description>Pain Relief Rating (PRR): scored on the 5-point Categorical Pain Relief Rating Scale (0=No relief to 4=Complete relief) at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PID</measure>
    <time_frame>0-8 hours</time_frame>
    <description>Pain Intensity Difference (PID): calculated as the baseline 11-point Numerical Pain Severity Rating (NPSR) minus the post-dose NPSR at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ibuprofen/Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen/Caffeine</intervention_name>
    <description>Ibuprofen/Caffeine fixed-dose combination</description>
    <arm_group_label>Ibuprofen/Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen capsule</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 16 years to 40 years of age (inclusive).

          -  Subjects who have undergone outpatient surgical extraction of 3 or more third molars,
             of which at least 2 must be a partial or complete bony mandibular impaction within 30
             days of Screening and have met baseline pain criteria as described in this protocol

          -  Examined by the attending dentist or physician and medically cleared to participate in
             the study.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic,
             metabolic or allergic disease (including drug allergies, but excluding untreated,
             asymptomatic, seasonal allergies at the time of dosing) determined by the Investigator
             to place the subject at increased risk including the presence or history within 2
             years of screening of the following medical conditions/disorders:

               -  Bleeding disorder;

               -  Gastrointestinal ulcer or gastrointestinal bleeding;

               -  Paralytic ileus or other gastrointestinal obstructive disorders.

          -  Pregnant female subjects; breastfeeding female subjects; fertile male subjects and
             female subjects of childbearing potential who are unwilling or unable to use a highly
             effective method of contraception

          -  Hypersensitivity to ibuprofen, naproxen, aspirin, or any other NSAID, caffeine, or
             other component of the product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3741002&amp;StudyName=A+Phase+3%2C+Randomized%2C+Double-blind%2C+Placebo-controlled+Study+Comparing+The+Analgesic+Efficacy+And+Safety+Of+A+Single+Oral+Dose+Of+A+Novel+Fixed-dose+Combination+Of+Ibuprofen+400+Mg+With+Caffeine+100+Mg+To+Ibuprofen+400+Mg+And+To+Placebo+In+The+Treatment+Of+Post-surgical+Dental+Pain+In+Otherwise+Healthy+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>third molar extraction</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>ibuprofen/caffeine</keyword>
  <keyword>post-surgical dental pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

